Infusion System for Kidney Patients

A new system is designed for the administration of physician-specified medications and other therapeutic agents directly into the renal arteries of patients with kidney dysfunction who may benefit from targeted renal therapy (TRT), including those with congestive heart failure. The system has been cleared by the U.S. Food and Drug Administration (FDA).

The Benephit Delta system is an alternative to the standard delivery method of systemic intravenous (IV) infusion of medications to treat kidney dysfunction related to cardiovascular disease, kidney failure, and congestive heart failure (CHF). An earlier version of the system was limited to use in the interventional laboratory, where a single catheter is placed in a femoral artery access site in the patient's groin enabling interventional procedures to take place concurrently with TRT.

The reduced profile, increased flexibility, and longer lengths of the Benephit Delta system allow for access through arterial sites such as the arm. The system is designed to allow greater patient mobility and ease in providing therapy once the patient leaves the interventional laboratory. Patients who may benefit from this approach to TRT include CHF patients who develop kidney dysfunction and patients with acute renal failure.

"In addition to congestive heart failure patients who develop cardiorenal syndrome, the Delta system might also be used to provide therapy to patients who develop acute kidney failure while in the intensive care unit, during or after surgery,” commented Paul Teirstein, M.D., director of interventional cardiology, Division of Cardiovascular Diseases, Scripps Clinic (La Jolla, CA, USA).

The Benephit Delta system was developed by FlowMedica (Fremont, CA, USA).






Related Links:
FlowMedica